MedPath

Arranon

These highlights do not include all the information needed to use ARRANON safely and effectively. See full prescribing information for ARRANON. ARRANON (nelarabine) injection, for intravenous use Initial U.S. Approval: 2005

Approved
Approval ID

fffa5d75-0dba-4ad7-a252-5f60fa28489a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 8, 2022

Manufacturers
FDA

Novartis Pharmaceuticals Corporation

DUNS: 002147023

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

nelarabine

PRODUCT DETAILS

NDC Product Code0078-0683
Application NumberNDA021877
Marketing CategoryC73594
Route of AdministrationINTRAVENOUS
Effective DateSeptember 8, 2022
Generic Namenelarabine

INGREDIENTS (3)

NELARABINEActive
Quantity: 5 mg in 1 mL
Code: 60158CV180
Classification: ACTIB
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Arranon - FDA Drug Approval Details